Publications by authors named "Rainer Brachmann"

Claim this Profile
P
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Jennifer R Diamond, Carlos Becerra, Donald Richards, Alain Mita, Cynthia Osborne, Rainer K Brachmann

Breast Cancer Res Treat· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Efrat Dotan, Dana B Cardin, Heinz-Josef Lenz, Wells Messersmith, Bert O'Neil, Rainer K Brachmann

Clin Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Kathleen N Moore, Camille C Gunderson, Paul Sabbatini, D Scott McMeekin, Gina Mantia-Smaldone, Rainer Karl Brachmann

Gynecol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Rainer K Brachmann

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Colin D Weekes, Muralidhar Beeram, Anthony W Tolcher, Kyriakos P Papadopoulos, Lia Gore, Rainer K Brachmann

Invest New Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, Kyriakos P Papadopoulos, Lia Gore, Rainer K Brachmann

Cancer Chemother Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Jill M Spoerke, Carol O'Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K Brachmann

Clin Cancer Res· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D Weekes, Rainer Brachmann

Clin Cancer Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.
Yan Xin, Shuang Bai, Lisa A Damico-Beyer, Denise Jin, Wei-Ching Liang, Rainer K Brachmann

Pharm Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.
Takahiko Kobayashi, Junich Ishida, Manabu Musashi, Shuichi Ota, Takeshi Yoshida, Rainer K Brachmann

Int J Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
hADA2a and hADA3 are required for acetylation, transcriptional activity and proliferative effects of beta-catenin.
Min Yang, Marian L Waterman, Rainer K Brachmann

Cancer Biol Ther· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteins.
Jue Zeng, Jizhou Yan, Ting Wang, Deborah Mosbrook-Davis, Kyle T Dolan, Rainer K Brachmann

Nucleic Acids Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGED2: a novel p53-dissociator.
Chris Papageorgio, Rainer Brachmann, Jue Zeng, Robert Culverhouse, Wanghai Zhang

Int J Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53.
Ting Wang, Jue Zeng, Craig B Lowe, Robert G Sellers, Sofie R Salama, Rainer K Brachmann

Proc Natl Acad Sci U S A· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.
Samuel A Danziger, Jue Zeng, Ying Wang, Rainer K Brachmann, Richard H Lathrop

Bioinformatics· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Lawrence R Dearth, Hua Qian, Ting Wang, Timothy E Baroni, Jue Zeng, Rainer K Brachmann

Carcinogenesis· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneous biomedical database integration using a hybrid strategy: a p53 cancer research database.
Vadim Y Bichutskiy, Richard Colman, Rainer K Brachmann, Richard H Lathrop

Cancer Inform· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants.
Samuel A Danziger, S Joshua Swamidass, Jue Zeng, Lawrence R Dearth, Qiang Lu, Rainer K Brachmann

IEEE/ACM Trans Comput Biol Bioinform· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation.
Takahiko Kobayashi, Ting Wang, Masaji Maezawa, Masanobu Kobayashi, Shunsuke Ohnishi, Rainer K Brachmann

Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 mutants: the achilles' heel of human cancers?
Rainer K Brachmann

Cell Cycle· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATP, Cancer and p53.
Lawrence R Dearth, Rainer K Brachmann

Cancer Biol Ther· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A global suppressor motif for p53 cancer mutants.
Timothy E Baroni, Ting Wang, Hua Qian, Lawrence R Dearth, Lan N Truong, Rainer K Brachmann

Proc Natl Acad Sci U S A· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic strategies in Saccharomyces cerevisiae to study human tumor suppressor genes.
Takahiko Kobayashi, Ting Wang, Hua Qian, Rainer K Brachmann

Methods Mol Biol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.
Hua Qian, Ting Wang, Louie Naumovski, Charles D Lopez, Rainer K Brachmann

Oncogene· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis